If you need to contact our communication department, please do it by contacting:

  • Miguel Martínez-Cava
  • Olaya Fernández Díez
  • Pharma Mar Communication Dept.
  • Phone: +34 91 846 6000

Press releases

No posts found.

Sylentis receives authorisation to commence Phase IIb clinical trial with bamosiran (SYL040012) for treating ocular hypertension associated with glaucoma

The main endpoint of the trial is to establish the most effective dose of bamosiran for reducing intraocular pressure after 28 days’ treatment.  The Phase IIb trial with bamosiran will be conducted at 21 centres in Spain, Germany, Estonia and the United States, enrolling 180 patients. Madrid, 17 July 2014: Grupo

Sylentis reports positive Phase II results with SYL1001 in treating ocular pain related to dry eye syndrome

Sylentis reports positive Phase II results with SYL1001 in treating ocular pain related to dry eye syndrome Phase II dose-finding and efficacy trials (SYL1001_II and SYL1001_III) achieved their primary endpoints in terms of ocular pain (VAS) (p<0.016) and hyperaemia reduction with a dose of 1.125% (p<0.0134). SYL1001 was well tolerated

Sylentis announces new data on the treatment of allergic conjunctivitis

The results of SYL116011 have demonstrated that this treatment reduces the symptoms related to the allergy in 50% to 80%. The ARVO meeting has considered the poster presentation to be of scientific interest, contributing therefore to its release. Around 30% of the worldwide population show allergic symptoms and between 40-80%

Sylentis participates in the 7th Spanish Conference on Glaucoma (SEG)

Madrid, 9 March 2011: Sylentis (MC:ZEL) presented the main results of its Phase I trial on safety and tolerance of its product SYL040012; the compound proved to be safe in the trial conditions. These results were presented in an oral communication entitled “Phase I Trial with SYL040012: New RNAi-based treatment for glaucoma”

Sylentis announces top-line results from Phase II study SYLTAG for RNAi drug bamosiran (SYL040012) in Glaucoma

All bamosiran doses similarly reduced the intraocular pressure (IOP). In patients with a baseline IOP greater than or equal to 25 mm Hg, 1.125% bamosiran showed more efficacy  The trial did not meet the secondary objective of demonstrating non-inferiority compared to timolol in the total patient population; however, bamosiran at

Alnylam Pharmaceuticals Grants InterfeRx(TM) Intellectual Property License to Sylentis for Development and Commercialization of RNAi Therapeutics

CAMBRIDGE, Mass. & MADRID–(BUSINESS WIRE)–Nov. 16, 2011— Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and Sylentis, S.A., a Spanish bio-pharmaceutical company devoted to the research and development of new therapies based on RNAi, announced today that Alnylam has granted Sylentis a non-exclusive option for a new target-specific

Sylentis announces new preclinical and clinical data for its SYL1001 molecule during ARVO 2017

SYL1001 is a compound under investigation for the treatment of dry eye disease. It is a product based on the novel technology RNA interference (RNAi), developed for the treatment of signs and symptoms of this illness. At the Annual Congress of the Association for Research in Vision and Ophthalmology 2017,

Sylentis sponsors the 11th OTS’s Annual Meeting

Sylentis sponsors the 11th Annual meeting of the Oligonucleotide Therapeutics Society (OTS). The meeting will be held in Leiden (The Netherlands) 11-14th October, 2015. Oligonucleotide Therapeutics Society is an open, nonprofit forum to foster academia and industry-based research and development of oligonucleotide therapeutics. You can find more information about this event

Sylentis presents new data on a new eye drop siRNA for the treatment of retinal diseases avoiding intraocular injections

This new investigational treatment, based on RNA interference, reaches the retina when administered in eye drops. This feature is expected to positively affect patients’ quality of life by eluding the use of current standard treatments administered by intraocular injections.   Madrid, 25 September 2017. Sylentis presents, for the first time,

Sylentis, a PharmaMar Group Company, to present new data at ARVO 2023

Sylentis, a PharmaMar Group Company (MSE:PHM), has announced today that it is presenting at ARVO 2023 advances on two of its ophthalmic studies based on RNA interference (RNAi) technology: Tivanisiran, for Dry Eye Disease (DED); and SYL1801, for retinal diseases such as Age-related Macular Degeneration (AMD). The Company is also
error: Content is protected !!